Wen PY, Reardon DA. Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69–70.

Article  CAS  PubMed  Google Scholar 

Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

Article  CAS  PubMed  Google Scholar 

Hölzer T, Herholz K, Jeske J, Heiss W-D. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J computer Assist Tomogr. 1993;17:681–7.

Article  Google Scholar 

Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J neuro-Oncol. 2009;92:317–35.

Article  CAS  Google Scholar 

Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol. 2005;7:134–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell. 2009;15:501–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay R, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α. Oncogene. 2009;28:3949–59.

Article  CAS  PubMed  Google Scholar 

Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, et al. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 2021;11:665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, et al. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. Int J Oncol. 2014;44:2121–31.

Article  CAS  PubMed  Google Scholar 

Hjelmeland AB, Wu Q, Heddleston J, Choudhary G, MacSwords J, Lathia J, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011;18:829–40.

Article  CAS  PubMed  Google Scholar 

Samanta D, Semenza GL. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. Biochimica et Biophysica Acta (BBA)-Rev Cancer. 2018;1870:15–22.

Article  CAS  Google Scholar 

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunbar E, Coats B, Shroads A, Langaee T, Lew A, Forder J, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Investigational N. drugs. 2014;32:452–64.

Article  CAS  Google Scholar 

Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncol. 2022;24:1935–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1003–10.

Article  PubMed  Google Scholar 

Michelakis E, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2:31ra4.

Article  Google Scholar 

Strowd R, Ellingson B, Raymond C, Yao J, Wen PY, Ahluwalia M, et al. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. J neuro-Oncol. 2023;165:1–12.

Article  Google Scholar 

Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, et al. Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma. Front Oncol. 2018;8:462.

Article  PubMed  PubMed Central  Google Scholar 

Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics. 2022;12:4734–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu H, Qiu W, Sun T, Wang L, Du C, Hu Y, et al. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Acta Pharmaceutica Sin B. 2022;12:1781–804.

Article  CAS  Google Scholar 

Sánchez-Castillo A, Vooijs M, Kampen KR. Linking serine/glycine metabolism to radiotherapy resistance. Cancers. 2021;13:1191.

Article  PubMed  PubMed Central  Google Scholar 

Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491:458–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109:6904–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi S, et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell death Dis. 2013;4:e877.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR. The ins and outs of serine and glycine metabolism in cancer. Nat Metab. 2021;3:131–41.

Article  CAS  PubMed  Google Scholar 

Meiser J, Tumanov S, Maddocks O, Labuschagne CF, Athineos D, Van Den Broek N, et al. Serine one-carbon catabolism with formate overflow. Sci Adv. 2016;2:e1601273.

Article  PubMed  PubMed Central  Google Scholar 

Yang L, Canaveras JCG, Chen Z, Wang L, Liang L, Jang C, et al. Serine catabolism feeds NADH when respiration is impaired. Cell Metab. 2020;31:809–21.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ju H-Q, Lin J-F, Tian T, Xie D, Xu R-H. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5:231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engel AL, Lorenz NI, Klann K, Münch C, Depner C, Steinbach JP, et al. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer. 2020;122:1391–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015;520:363–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka K, Sasayama T, Nagashima H, Irino Y, Takahashi M, Izumi Y, et al. Glioma cells require one-carbon metabolism to survive glutamine starvation. Acta Neuropathologica Commun. 2021;9:1–14.